8-K filing — Pyxis Oncology, Inc. (PYXS)
Filed: 2026-10-01 AccNo: 0001437749-26-031767 Size: 828 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8
Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $8.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Pyxis Oncology shares are trading lower after the company announced the pricing of its $110 million offering of 36,047,919 shares at $2.90 with common warrants for 49,310,352 shares at a $3.50 exercise price.
Pyxis Oncology Prices $110M Offering Of 36,047,919 Shares At $2.90 With Common Warrants For 49,310,352 Shares At $3.50 Exercise Price
Pyxis Oncology Launches Public Offering Of Common Stock/Pre-Funded Warrants And Warrants To Fund MICVO Phase 3 Development; No Terms Disclosed